^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    MCARH109

    i
    Associations
    News

    Trials

    Company:
    BMS, Eureka Therap, Memorial Sloan-Kettering Cancer Center, Sanofi
    Drug class:
    GPRC5D-targeted CAR-T immunotherapy
    Related drugs:
    Associations
    News

    Trials

    Apply
    MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma (NCT04555551)
    Phase 1
    Memorial Sloan Kettering Cancer Center
    Active, not recruiting
    Last update posted :
    07/24/2023
    Initiation :
    09/08/2020
    Primary completion :
    08/01/2024
    Completion :
    08/01/2024
    SDC1
    |
    MCARH109
    A Study of MCARH109 and MCARH125 in People With Multiple Myeloma (NCT05431608)
    Phase 1
    Memorial Sloan Kettering Cancer Center
    Recruiting
    Last update posted :
    07/14/2023
    Initiation :
    06/20/2022
    Primary completion :
    06/20/2024
    Completion :
    06/20/2024
    SDC1
    |
    MCARH109 • MCARH125